[Somatic and psychosocial therapy concepts in multiple sclerosis (I)].
D001379:Azathioprine / Q000627:therapeutic use; D001561:Benzilates; D002086:Butylscopolammonium Bromide / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004041:Dietary Fats; D004629:Emepronium / Q000627:therapeutic use; D005231:Fatty Acids, Unsaturated; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000628:therapy*; D009662:Nortropanes / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011602:Psychophysiologic Disorders / Q000628:therapy*; D011759:Pyrrolidines / Q000627:therapeutic use; D014546:Urinary Catheterization; D014555:Urination Disorders / Q000188:drug therapy
D001561:Benzilates; D004041:Dietary Fats; D005231:Fatty Acids, Unsaturated; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009662:Nortropanes; D010276:Parasympatholytics; D011759:Pyrrolidines; D004629:Emepronium; D010643:Phenoxybenzamine; C003330:trospium chloride; D002086:Butylscopolammonium Bromide; D003520:Cyclophosphamide; D001379:Azathioprine
Somatische und psychosoziale Therapiekonzepte bei der multiplen Sklerose (I).